Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI

Watchlist Manager
Brainstorm Cell Therapeutics Inc Logo
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Watchlist
Price: 0.6 USD
Market Cap: 6.2m USD

Relative Value

There is not enough data to reliably calculate the relative value of BCLI.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BCLI Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-12.2
Industry
24
Forward
-0.4
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-13.4
Industry
21.6
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-13.4
Industry
23.7
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-1.1
Industry
3.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-12.2
Industry
6.7
Forward
-0.4
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-12.1
Industry
7.2
Forward
-0.4
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-13.3
Industry
8.2
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-13.3
Industry
6.7
vs History
vs Industry
4
Median 3Y
-14.3
Median 5Y
-1.5
Industry
5.7

Multiples Across Competitors

BCLI Competitors Multiples
Brainstorm Cell Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
6.2m USD 0 -0.6 -0.5 -0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
395.7B USD 6.6 168.7 16.3 23.2
US
Amgen Inc
NASDAQ:AMGN
172.3B USD 4.8 24.6 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
150.4B USD 5.2 18.6 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD 9.6 30.6 22.5 23.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.2B USD 5.2 16.2 15.4 17.4
AU
CSL Ltd
ASX:CSL
88B AUD 3.7 19.4 13.1 16.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.7B USD 17.7 1 300.9 171.3 207.7
NL
argenx SE
XBRU:ARGX
47.4B EUR 15.3 36 62.4 64.1
P/E Multiple
Earnings Growth PEG
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average P/E: 201.9
Negative Multiple: -0.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.6
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
9%
1.8
AU
CSL Ltd
ASX:CSL
19.4
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 300.9
N/A N/A
NL
argenx SE
XBRU:ARGX
36
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average EV/EBITDA: 41.4
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
171.3
N/A N/A
NL
argenx SE
XBRU:ARGX
62.4
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Brainstorm Cell Therapeutics Inc
NASDAQ:BCLI
Average EV/EBIT: 47.8
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
207.7
N/A N/A
NL
argenx SE
XBRU:ARGX
64.1
N/A N/A